Literature DB >> 10646497

An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression.

A Zimprich1, J Kraus, M Wöltje, P Mayer, E Rauch, V Höllt.   

Abstract

Prodynorphin, the precursor of the dynorphin opioid peptides, has been shown to play an important role in several aspects of human diseases and complex traits, e.g., drug abuse, epilepsy, and mood disorders. The objective of this study was to identify polymorphisms in the 5' control region of the human prodynorphin gene and to relate these polymorphisms to prodynorphin gene expression. Within the core promoter region, a 68-bp sequence was found to occur as a polymorphic element, either singular or as tandemly repeated element two, three, or four times. This 68-bp repeat element contains an AP-1 transcription factor binding site as demonstrated by electrophoretic mobility shift assay. Reporter gene assays were performed and provided evidence for allele dependent different promoter activity. Dynorphin was found to be involved in many pathophysiological processes so that the described prodynorphin alleles may correlate with the occurrence of several diseases, for example, drug addiction. However, prodynorphin allelic distributions were not significantly different in heroin addicts and control subjects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646497     DOI: 10.1046/j.1471-4159.2000.740472.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  44 in total

Review 1.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

2.  Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use.

Authors:  Vadim Yuferov; Matthew Randesi; Eduardo R Butelman; Wim van den Brink; Peter Blanken; Jan M van Ree; Jürg Ott; Mary Jeanne Kreek
Journal:  Neurosci Lett       Date:  2019-03-29       Impact factor: 3.046

Review 3.  An overview of the genetics of substance use disorders.

Authors:  H M Lachman
Journal:  Curr Psychiatry Rep       Date:  2006-04       Impact factor: 5.285

Review 4.  Role of a functional human gene polymorphism in stress responsivity and addictions.

Authors:  M J Kreek
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

Review 5.  Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment.

Authors:  Vadim Yuferov; Orna Levran; Dmitri Proudnikov; David A Nielsen; Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

6.  Alcohol dependence, disinhibited behavior and variation in the prodynorphin gene.

Authors:  Janine D Flory; Carolyn L Pytte; Yasmin Hurd; Robert E Ferrell; Stephen B Manuck
Journal:  Biol Psychol       Date:  2011-07-05       Impact factor: 3.251

7.  Prodynorphin gene promoter polymorphism and temporal lobe epilepsy: A meta-analysis.

Authors:  Na Zhang; Tao-Hui Ouyang; Qing Zhou; Hui-Cong Kang; Sui-Qiang Zhu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

8.  A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats.

Authors:  Jennifer M Mitchell; Marisa T Liang; Howard L Fields
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

9.  A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain.

Authors:  Vadim Yuferov; Fei Ji; David A Nielsen; Orna Levran; Ann Ho; Susan Morgello; Ruijin Shi; Jurg Ott; Mary Jeanne Kreek
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

Review 10.  Genes associated with addiction: alcoholism, opiate, and cocaine addiction.

Authors:  Mary Jeanne Kreek; David A Nielsen; K Steven LaForge
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.